SCHEMBL2850273

SCHEMBL2850273

Cc1cccc(-c2c(Cl)cccc2C(=O)C2CCCN(C(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.49
KAT5 Q92993 2/20 0.49
USP30 Q70CQ3 3/20 0.46
POLB P06746 1/20 0.46
GPR119 Q8TDV5 1/20 0.45
KAT7 O95251 1/20 0.43
STS P08842 2/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
ACKR3 P25106 1/20 0.41
HSD11B1 P28845 1/20 0.41
REN P00797 1/20 0.40
RHOA P61586 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850274 1.00 KAT6A (0.49) KAT6AKAT5USP30POLBGPR119
SCHEMBL3571520 0.90 KAT6A (0.46) KAT6AKAT5USP30GPR119KAT7
SCHEMBL3565628 0.90 KAT6A (0.46) KAT6AKAT5USP30GPR119KAT7
SCHEMBL3123201 0.88 USP30 (0.47) KAT6AKAT5USP30POLBSTS
SCHEMBL3123197 0.88 USP30 (0.47) KAT6AKAT5USP30POLBSTS
SCHEMBL2847273 0.86 POLB (0.47) POLBMEN1ALDH1A1KMT2AHSD11B1
SCHEMBL5604174 0.84 POLB (0.43) POLBMAPTMEN1ALDH1A1KMT2A
SCHEMBL5592323 0.83 POLB (0.42) POLBMAPTMEN1ALDH1A1KMT2A
SCHEMBL970360 0.81 POLB (0.51) KAT6AKAT5USP30POLBSTS
SCHEMBL970359 0.81 POLB (0.51) KAT6AKAT5USP30POLBSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-20100317697-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-12-16 US disclosed
US-20100280005-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-11-04 US disclosed
US-20100179109-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-07-15 US disclosed
US-20100179109-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-07-15 US disclosed
US-20100179109-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-07-15 US disclosed
US-20100130471-A1 Renin Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-05-27 US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
EP-2010488-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2009-01-07 EP disclosed
WO-2008124575-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-16 WO disclosed
WO-2007117559-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179109-A1 RENIN INHIBITORS REN, ACE, AGTR1 KAT6A 3854/4885KAT5 4456/4885USP30 2211/4885
US-20100280005-A1 Renin Inhibitors REN, ACE, AGTR1 KAT6A 3754/4885KAT5 4358/4885USP30 2118/4885
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 KAT6A 4428/4885KAT5 4181/4885USP30 1423/4885
US-20100317697-A1 Renin Inhibitors REN, ACE, SERPINB1 KAT6A 4103/4885KAT5 4326/4885USP30 2244/4885
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors REN, ACE, PREP KAT6A 2746/4885KAT5 3064/4885USP30 2954/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 KAT6A 4029/4885KAT5 4184/4885USP30 1468/4885
US-20100130471-A1 Renin Inhibitors ACE, REN, DNPEP KAT6A 3919/4885KAT5 4274/4885USP30 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.